Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 16 May 2020)

 

Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland
An infection with high-risk human papillomavirus (HPV) is the obligatory aetiological factor for the development of cervical cancer. In Switzerland, the prevention strategy for cervical cancer is based on prim…
Authors: André B. Kind, Andrew Pavelyev, Smita Kothari, Nadia El Mouaddin, Aurélie Schmidt, Edith Morais, Patrik Guggisberg and Florian Lienert
Citation: BMC Public Health 2020 20:671
Content type: Research article
Published on: 12 May 2020